Desloratadine
- PDF / 420,166 Bytes
- 27 Pages / 504.57 x 720 pts Page_size
- 35 Downloads / 154 Views
ADIS DRUG EVALUATION
© Adis Data Information BV 2003. All rights reserved.
Desloratadine An Update of its Efficacy in the Management of Allergic Disorders David Murdoch, Karen L. Goa and Susan J. Keam Adis International Limited, Auckland, New Zealand Various sections of the manuscript reviewed by: D.K. Agrawal, Center for Allergy, Asthma and Immunology, Creighton University School of Medicine, Omaha, Nebraska, USA; W.E. Berger, Southern California Research, Mission Viejo, California, USA; L.M. DuBuske, Immunology Research Institute of New England, Gardner, Massachusetts, USA; A. Gauger, Klink ¨ Dermatologie und Allergologie am Biederstein, Technische Universit¨at Munchen, ¨ und Poliklinik fur Munich, Germany; B.M. Henz, Department of Dermatology Charite, Humboldt University, Berlin, Germany; F. Horak, ENT-University Clinic AKH Vienna, University of Vienna, Vienna, Austria; G.K. Scadding, Royal National Throat, Nose and Ear Hospital, London, UK; E. Schenkel, Valley Clinical Research Center, Easton, Pennsylvania, USA. Data Selection Sources: Medical literature published in any language since 1980 on desloratadine, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: Medline search terms were ‘desloratadine’ or ‘SCH-34117’. EMBASE search terms were ‘desloratadine’ or ‘SCH-34117’. AdisBase search terms were ‘desloratadine’ or ‘SCH 34117’. Searches were last updated 23 July 2003. Selection: Studies in patients with allergic disorders (i.e. seasonal allergic rhinitis with or without bronchial asthma, perennial allergic rhinitis or chronic idiopathic urticaria) who received desloratadine. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included. Index terms: Seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), chronic idiopathic urticaria (CIU), desloratadine, histamine H1-receptor antagonist, H1-antihistamine, pharmacodynamics, pharmacokinetics, therapeutic use.
Contents Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2052 1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2056 2. Pharmacodynamic Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2056 2.1 Receptor Binding Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2056 2.2 Antihistamine
